has function has role vaccinated in route immunizes against disease immunizes recipient brain cancer Homo sapiens subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role brain cancer vaccine therapeutic cancer vaccine H3.3K27M-specific peptide vaccine VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6295 Jie Zheng cancer vaccine 6295 NCT: https://clinicaltrials.gov/study/NCT04749641 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684 A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells. Hayleigh Kahn